Guidance for Industry and Food and Drug Administration Staff; “`Harmful and Potentially Harmful Constituents' in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act”; Availability, 5387-5388 [2011-1990]
Download as PDF
Federal Register / Vol. 76, No. 20 / Monday, January 31, 2011 / Notices
jlentini on DSKJ8SOYB1PROD with NOTICES
finalized, will supersede the FDA
memorandum issued on May 29, 1996,
entitled ‘‘Recommendations and
Licensure Requirements for LeukocyteReduced Blood Products.’’
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by May 2, 2011.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Office of Communication, Outreach and
Development (HFM–40), Center for
Biologics Evaluation and Research
(CBER), Food and Drug Administration,
1401 Rockville Pike, suite 200N,
Rockville, MD 20852–1448. Send one
self-addressed adhesive label to assist
the office in processing your requests.
The draft guidance may also be obtained
by mail by calling CBER at 1–800–835–
4709 or 301–827–1800. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Lori
Jo Churchyard, Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration, 1401
Rockville Pike, suite 200N, Rockville,
MD 20852–1448, 301–827–6210.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a revised, second draft document
entitled ‘‘Guidance for Industry: PreStorage Leukocyte Reduction of Whole
Blood and Blood Components Intended
for Transfusion’’ dated January 2011.
The draft guidance document provides
blood establishments with
recommendations for pre-storage
leukocyte reduction of Whole Blood and
blood components intended for
transfusion, including recommendations
for validation and quality control
monitoring of the leukocyte reduction
process. The draft guidance provides
information to assist licensed blood
establishments for submitting biologics
license application supplements to
include leukocytes reduced
components. This second draft guidance
document incorporates revisions after
reviewing comments on the January
2001 draft, and in consideration of
VerDate Mar<15>2010
16:38 Jan 28, 2011
Jkt 223001
additional public discussions held at
the June and December 2001 meetings of
the Blood Products Advisory Committee
and the July 2005 public workshop
entitled ‘‘Update on Leukocyte
Reduction of Blood and Blood
Components.’’ This draft guidance
replaces the draft guidance of the same
title dated January 2001 (January 31,
2001, 66 FR 8410). The draft guidance,
when finalized, will supersede the FDA
memorandum issued on May 29, 1996,
entitled ‘‘Recommendations and
Licensure Requirements for LeukocyteReduced Blood Products.’’
The draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent FDA’s current thinking on this
topic. It does not create or confer any
rights for or on any person and does not
operate to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the requirement
of the applicable statutes and
regulations.
II. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR part 607 have
been approved under OMB control
number 0910–0052; the collections of
information in 21 CFR 606.100(b),
606.100(c), and 606.121 have been
approved under OMB control number
0910–0116; the collections of
information in 21 CFR 211.192 and
211.198 have been approved under
OMB control number 0910–0139; and
the collections of information in 21 CFR
601.12 and 610.60 have been approved
under OMB control number 0910–0338.
III. Comments
The draft guidance is being
distributed for comment purposes only
and is not intended for implementation
at this time. Interested persons may
submit to the Division of Dockets
Management (see ADDRESSES) either
electronic or written comments
regarding this document. It is only
necessary to send one set of comments.
It is no longer necessary to send two
copies of mailed comments. Identify
comments with the docket number
found in brackets in the heading of this
document. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
5387
IV. Electronic Access
Persons with access to the Internet
may obtain the draft guidance at either
https://www.fda.gov/
BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm or
https://www.regulations.gov.
Dated: January 25, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–1989 Filed 1–28–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–D–0281]
Guidance for Industry and Food and
Drug Administration Staff; ‘‘‘Harmful
and Potentially Harmful Constituents’
in Tobacco Products as Used in
Section 904(e) of the Federal Food,
Drug, and Cosmetic Act’’; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
and FDA staff entitled ‘‘‘Harmful and
Potentially Harmful Constituents’ in
Tobacco Products as Used in Section
904(e) of the Federal Food, Drug, and
Cosmetic Act.’’ This guidance provides
written guidance to industry and FDA
staff on certain provisions of the Family
Smoking Prevention and Tobacco
Control Act (Tobacco Control Act).
DATES: Submit either electronic or
written comments on this guidance at
any time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Center for Tobacco Products, Food and
Drug Administration, 9200 Corporate
Blvd., Rockville, MD 20850–3229. Send
one self-addressed adhesive label to
assist that office in processing your
requests or include a fax number to
which the guidance document may be
sent. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the guidance document.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
SUMMARY:
E:\FR\FM\31JAN1.SGM
31JAN1
5388
Federal Register / Vol. 76, No. 20 / Monday, January 31, 2011 / Notices
FOR FURTHER INFORMATION CONTACT:
Carol Drew, Center for Tobacco
Products, Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850–3229, 301–796–
3505.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 10,
2010 (75 FR 32952), FDA announced the
availability of a draft guidance entitled
‘‘‘Harmful and Potentially Harmful
Constituents’ in Tobacco Products as
Used in Section 904(e) of the Federal
Food, Drug, and Cosmetic Act.’’ The
Agency considered received comments
as it finalized this guidance. The
guidance document discusses the
meaning of the term ‘‘harmful and
potentially harmful constituent’’ in the
context of implementing the listing
requirements of section 904(e) of the
Federal Food, Drug, and Cosmetic Act
(the FD&C Act) (21 U.S.C. 387d(e)).
On June 22, 2009, the President
signed the Tobacco Control Act (Pub. L.
111–310) into law. The Tobacco Control
Act amended the FD&C Act by, among
other things, adding a new chapter
granting FDA important new authority
to regulate the manufacture, marketing,
and distribution of tobacco products to
protect the public health generally and
to reduce tobacco use by minors.
Section 904(e) of the FD&C Act, as
added by the Tobacco Control Act,
requires FDA to establish, and
periodically revise as appropriate, ‘‘a list
of harmful and potentially harmful
constituents, including smoke
constituents, to health in each tobacco
product by brand and by quantity in
each brand and subbrand.’’ The
guidance discusses the meaning of the
term ‘‘harmful and potentially harmful
constituent’’ in the context of
implementing the listing requirements
of section 904(e).
jlentini on DSKJ8SOYB1PROD with NOTICES
II. Significance of Guidance
This guidance is being issued as a
level 1 guidance consistent with FDA’s
good guidance practices regulation (21
CFR 10.115). The guidance represents
the Agency’s current thinking on the
meaning of the term ‘‘harmful and
potentially harmful constituents’’ in the
context of section 904(e) of the FD&C
Act. It does not create or confer any
rights for or on any person and does not
operate to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
VerDate Mar<15>2010
16:38 Jan 28, 2011
Jkt 223001
III. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
IV. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.regulations.gov or https://
www.fda.gov/TobaccoProducts/
GuidanceCompliance
RegulatoryInformation/default.htm.
Dated: January 25, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–1990 Filed 1–28–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection:
Comment Request
In compliance with the requirement
for opportunity for public comment on
proposed data collection projects
(section 3506(c)(2)(A) of Title 44, United
States Code, as amended by the
Paperwork Reduction Act of 1995, Pub.
L. 104–13), the Health Resources and
Services Administration (HRSA)
publishes periodic summaries of
proposed projects being developed for
submission to the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and draft instruments, e-mail
paperwork@hrsa.gov or call the HRSA
Reports Clearance Officer at (301) 443–
1129.
Comments are invited on: (a) The
proposed collection of information for
the proper performance of the functions
of the Agency; (b) the accuracy of the
Agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
use of automated collection techniques
or other forms of information
technology.
Proposed Project: Ryan White HIV/
AIDS Program Part F Dental Services
Report (OMB No. 0915–0151)—
[Extension]
The Dental Reimbursement Program
(DRP) and the Community Based Dental
Partnership Program under Part F of the
Ryan White HIV/AIDS Program, offer
funding to accredited dental education
programs to support the provision of
oral health services for HIV-positive
individuals. Institutions eligible for
these Ryan White HIV/AIDS Programs
are accredited schools of dentistry, postdoctoral dental education programs, and
dental hygiene programs.
The DRP Application is the Dental
Services Report that schools and
programs use to apply for funding of
non-reimbursed costs incurred in
providing oral health care to patients
with HIV, or to report annual program
data. Awards are authorized under
section 2692(b) of the Public Health
Service Act (42 U.S.C. 300ff–111(b). The
Dental Services Report collects data in
four different areas: Program
information, patient demographics and
services, funding, and training. It also
requests applicants to provide narrative
descriptions of their services and
facilities, as well as their links and
collaboration with community-based
providers of oral health services.
The primary purpose of collecting this
information annually is to verify
eligibility and determine reimbursement
amounts for DRP applicants, as well as
to document the program
accomplishments of Community-Based
Dental Partnership Program grant
recipients. This information also allows
HRSA to learn about (1) the extent of the
involvement of dental schools and
programs in treating patients with HIV,
(2) the number and characteristics of
clients who receive HIV/AIDS programsupported oral health services, (3) the
types and frequency of the provision of
these services, (4) the non-reimbursed
costs of oral health care provided to
patients with HIV, and (5) the scope of
grant recipients’ community-based
collaborations and training of providers.
In addition to meeting the goal of
accountability to Congress, clients,
advocacy groups, and the general
public, information collected in the
Dental Services Report is critical for
HRSA, state and local grantees, and
individual providers, to help assess the
status of existing HIV-related health
service delivery systems.
The annual estimate of burden is as
follows:
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 76, Number 20 (Monday, January 31, 2011)]
[Notices]
[Pages 5387-5388]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-1990]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-D-0281]
Guidance for Industry and Food and Drug Administration Staff;
```Harmful and Potentially Harmful Constituents' in Tobacco Products as
Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act'';
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry and FDA staff entitled
```Harmful and Potentially Harmful Constituents' in Tobacco Products as
Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act.''
This guidance provides written guidance to industry and FDA staff on
certain provisions of the Family Smoking Prevention and Tobacco Control
Act (Tobacco Control Act).
DATES: Submit either electronic or written comments on this guidance at
any time.
ADDRESSES: Submit written requests for single copies of this guidance
to the Center for Tobacco Products, Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850-3229. Send one self-addressed
adhesive label to assist that office in processing your requests or
include a fax number to which the guidance document may be sent. See
the SUPPLEMENTARY INFORMATION section for electronic access to the
guidance document.
Submit electronic comments on the guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
[[Page 5388]]
FOR FURTHER INFORMATION CONTACT: Carol Drew, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850-3229, 301-796-3505.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 10, 2010 (75 FR 32952), FDA
announced the availability of a draft guidance entitled ```Harmful and
Potentially Harmful Constituents' in Tobacco Products as Used in
Section 904(e) of the Federal Food, Drug, and Cosmetic Act.'' The
Agency considered received comments as it finalized this guidance. The
guidance document discusses the meaning of the term ``harmful and
potentially harmful constituent'' in the context of implementing the
listing requirements of section 904(e) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 387d(e)).
On June 22, 2009, the President signed the Tobacco Control Act
(Pub. L. 111-310) into law. The Tobacco Control Act amended the FD&C
Act by, among other things, adding a new chapter granting FDA important
new authority to regulate the manufacture, marketing, and distribution
of tobacco products to protect the public health generally and to
reduce tobacco use by minors. Section 904(e) of the FD&C Act, as added
by the Tobacco Control Act, requires FDA to establish, and periodically
revise as appropriate, ``a list of harmful and potentially harmful
constituents, including smoke constituents, to health in each tobacco
product by brand and by quantity in each brand and subbrand.'' The
guidance discusses the meaning of the term ``harmful and potentially
harmful constituent'' in the context of implementing the listing
requirements of section 904(e).
II. Significance of Guidance
This guidance is being issued as a level 1 guidance consistent with
FDA's good guidance practices regulation (21 CFR 10.115). The guidance
represents the Agency's current thinking on the meaning of the term
``harmful and potentially harmful constituents'' in the context of
section 904(e) of the FD&C Act. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of the applicable statutes and regulations.
III. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
IV. Electronic Access
Persons with access to the Internet may obtain the document at
either http:[sol][sol]www.regulations.gov or
http:[sol][sol]www.fda.gov/TobaccoProducts/
GuidanceComplianceRegulatoryInformation/default.htm.
Dated: January 25, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-1990 Filed 1-28-11; 8:45 am]
BILLING CODE 4160-01-P